DHEA & Pregnenolone: The Complete Guide

Overview

Dehydroepiandrosterone (DHEA) is the most abundant circulating steroid hormone in the human body. Produced primarily by the adrenal glands, DHEA functions as a prohormone — a precursor that the body converts into androgens (such as testosterone) and estrogens (such as estradiol). DHEA production peaks in early adulthood, typically between ages 20 and 30, and then declines steadily. By age 70–80, circulating DHEA levels are approximately 10–20% of peak values — a decline of roughly 80% (Orentreich et al., 1984).

Pregnenolone is sometimes called the "mother hormone" because it sits at the very top of the steroid hormone synthesis cascade. Synthesized from cholesterol, pregnenolone is the first step in producing virtually every steroid hormone in the body: cortisol, DHEA, progesterone, testosterone, estrogen, and aldosterone. Like DHEA, pregnenolone levels decline with age, though the decline is less dramatically documented in the literature.

The age-related decline in both hormones has driven interest in supplementation as a potential anti-aging intervention. The hypothesis is straightforward: if declining hormone precursors contribute to age-related changes in body composition, cognition, bone density, sexual function, and well-being, then restoring those precursors to youthful levels may slow or partially reverse those changes.

This hypothesis has been tested in several clinical trials with mixed results. Some studies — particularly the early DHEA trials — showed improvements in well-being, body composition, and immune function. Others, including larger and longer studies, have found minimal or no clinically significant benefit. The evidence for pregnenolone supplementation is considerably less developed, with most research focusing on neuropsychiatric applications.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The Steroid Hormone Cascade

All steroid hormones originate from a single precursor: cholesterol. The conversion pathway follows a branching cascade:

• Cholesterol → Pregnenolone (via the enzyme CYP11A1, also called P450scc — the rate-limiting step in steroid synthesis)
• Pregnenolone → Progesterone (via 3β-HSD enzyme) — leads to cortisol, aldosterone
• Pregnenolone → 17-OH-Pregnenolone → DHEA (via CYP17A1 enzyme)
• DHEA → Androstenedione → Testosterone (via 3β-HSD and 17β-HSD enzymes)
• Testosterone → Estradiol (via aromatase enzyme)
• DHEA → DHEA-S (via sulfotransferase — the primary circulating form, with a half-life of 10–20 hours compared to minutes for free DHEA)

This cascade explains why pregnenolone is called the "mother hormone" — it is the biochemical starting point for cortisol, aldosterone, DHEA, progesterone, testosterone, and estrogen. Supplementing pregnenolone theoretically provides substrate for the body to produce whichever downstream hormone it needs most.

DHEA as a Prohormone

DHEA itself has relatively weak androgenic activity. Its primary biological significance comes from its conversion into more potent hormones in peripheral tissues (intracrinology). Tissues such as skin, bone, breast, prostate, and brain contain the enzymes needed to convert DHEA into testosterone and estradiol locally, without requiring these hormones to travel through the bloodstream from the gonads (Labrie et al., 2005).

This peripheral conversion mechanism — sometimes called "intracrinology" — is particularly relevant in postmenopausal women and aging men, where gonadal hormone production declines but adrenal DHEA can still serve as a local source of sex steroids in target tissues.

Independent Biological Activity

Beyond serving as precursors, both DHEA and pregnenolone appear to have independent biological effects:

• DHEA: Modulates immune function (enhances Th1 immune response), has anti-glucocorticoid effects (counteracts some effects of cortisol), acts as a neurosteroid with effects on GABA and NMDA receptors, and demonstrates anti-inflammatory and antioxidant properties in cell culture and animal models (Hazeldine et al., 2010).
• Pregnenolone: Functions as a neurosteroid with modulatory effects on GABA-A, NMDA, and sigma-1 receptors. Pregnenolone sulfate enhances NMDA receptor activity and has been associated with improved memory and cognitive function in animal models (Marx et al., 2011).

The Age-Related Decline

DHEA-S levels follow a characteristic age-related pattern, sometimes called "adrenopause":

Whether this decline is pathological (something that should be treated) or physiological (a normal part of aging) remains debated. This is the central question in DHEA supplementation research (Orentreich et al., 1984).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Landmark DHEA Trials

Morales et al. (1994) — The First Major Trial

This randomized, placebo-controlled crossover study administered 50 mg/day DHEA to 13 men and 17 women aged 40–70 for 3 months. Results showed restoration of DHEA-S to youthful levels and reported improvements in physical and psychological well-being, including increased energy, improved sleep quality, and enhanced sense of well-being. This study generated significant public interest in DHEA supplementation (Morales et al., 1994).

Baulieu et al. (2000) — The DHEAge Trial

The largest and most rigorous early DHEA trial: a randomized, double-blind, placebo-controlled study of 280 healthy men and women aged 60–79, receiving 50 mg/day DHEA or placebo for 12 months. Key findings:

• DHEA-S levels restored to youthful ranges in both sexes
• Improvements in bone mineral density observed in women over 70
• Improvements in skin hydration, thickness, and sebum production (particularly in women)
• Increased libido reported in women over 70
• No significant changes in body composition, muscle strength, or cognitive function
• No significant adverse effects

The DHEAge trial established that DHEA supplementation is generally safe in older adults but produced more modest benefits than earlier, smaller studies had suggested (Baulieu et al., 2000).

Nair et al. (2006) — The Mayo Clinic Trial

A rigorous 2-year randomized, double-blind, placebo-controlled trial of 87 elderly men and 57 elderly women receiving DHEA 75 mg/day (men) or 50 mg/day (women). This is among the largest and longest DHEA trials. Key findings:

• DHEA-S levels restored to young-adult ranges
• No significant improvements in body composition (fat mass, lean mass)
• No significant improvements in physical performance or quality of life
• No significant improvements in insulin sensitivity or lipid profiles
• Small increase in bone mineral density at some sites in women
• Well tolerated with no significant adverse effects

This trial was widely interpreted as demonstrating that DHEA supplementation, while safe, does not produce the broad anti-aging benefits initially hypothesized (Nair et al., 2006).

Additional DHEA Research Areas

• Adrenal insufficiency: DHEA supplementation (25–50 mg/day) has shown improvements in well-being, mood, and sexual function in women with primary and secondary adrenal insufficiency — a context where DHEA deficiency is more severe and clearly pathological (Arlt et al., 1999).
• Bone density: Multiple studies have shown modest improvements in bone mineral density with DHEA supplementation, particularly in older women. The effect size is generally smaller than that of bisphosphonates or hormone replacement therapy (Jankowski et al., 2006).
• Depression: Small trials have shown antidepressant effects of DHEA (up to 90 mg/day), with some evidence suggesting utility as an adjunct to antidepressant medications. Study sizes have been small (Schmidt et al., 2005).
• Immune function: DHEA supplementation has been associated with enhanced immune responses in elderly subjects, including improved vaccine responses and natural killer cell activity (Hazeldine et al., 2010).

Pregnenolone Research

Ritsner et al. (2010) — Pregnenolone and Cognition

A randomized, double-blind, placebo-controlled trial examining pregnenolone (30 mg/day escalated to 200 mg/day) as an adjunct treatment in patients with schizophrenia or schizoaffective disorder. Pregnenolone was associated with improvements in attention, working memory, and verbal fluency compared to placebo. The study suggested pregnenolone's neurosteroid activity may have cognitive-enhancing properties, though the findings are specific to a neuropsychiatric population (Ritsner et al., 2010).

• PTSD: Pregnenolone has been studied as a potential treatment for post-traumatic stress disorder, with pilot data suggesting possible benefits on PTSD symptoms and sleep quality (Marx et al., 2009).
• Traumatic brain injury: Preclinical studies have shown neuroprotective effects of pregnenolone and its metabolites following brain injury, leading to interest in clinical applications (Marx et al., 2011).

Limitations of the Research

• Mixed results for DHEA: The trajectory from promising small trials (Morales 1994) to underwhelming larger trials (Nair 2006) is a common pattern in supplement research. Early small studies may capture real subgroup effects or may overestimate benefits due to small sample sizes and publication bias.
• Limited pregnenolone data: The evidence base for pregnenolone supplementation in healthy adults is minimal. Most trials are in neuropsychiatric populations.
• Heterogeneous populations: DHEA's effects may differ meaningfully between men and women, between adrenally insufficient and healthy individuals, and across age ranges — making generalization from any single trial difficult.
• Surrogate endpoints: Many trials measure hormone levels or biomarkers rather than hard clinical outcomes (fractures, cardiovascular events, mortality).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

DHEA — Common Applications

Pregnenolone — Common Applications

FDA-Approved DHEA Product

One DHEA-derived product has FDA approval: prasterone (Intrarosa) — an intravaginal DHEA insert approved for the treatment of moderate-to-severe dyspareunia (painful intercourse) in postmenopausal women due to vulvar and vaginal atrophy. This is a prescription pharmaceutical product distinct from OTC DHEA supplements.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

DHEA Dosing

Sources: Baulieu et al., 2000 — DHEAge trial dosing · Nair et al., 2006 — DHEA in elderly men and women · Arlt et al., 1999 — DHEA replacement in adrenal insufficiency · Schmidt et al., 2005 — DHEA in depression

Pregnenolone Dosing

Dosing protocols above are derived from published clinical trials and reported clinical practice. Key references: Baulieu et al., 2000 · Nair et al., 2006 · Ritsner et al., 2010

Timing and Administration

• DHEA: Typically taken in the morning to mimic the natural diurnal rhythm of cortisol and DHEA production. Taking DHEA in the evening may interfere with sleep in some individuals.
• Pregnenolone: Can be taken morning or evening. Some practitioners recommend morning dosing; others suggest evening dosing may support sleep through downstream progesterone conversion.
• With or without food: Both are fat-soluble steroids and may be better absorbed with a meal containing dietary fat.

Lab Monitoring

Regular lab monitoring is recommended for anyone supplementing with DHEA or pregnenolone:

Sources: Labrie et al., 2005 — DHEA metabolism and intracrinology · Nair et al., 2006 — Monitoring protocol in 2-year DHEA trial

Labs should be checked at baseline (before starting), at 4–6 weeks after initiation, and periodically thereafter (every 3–6 months).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Users Report

DHEA — Reported Timeline

Sources: Morales et al., 1994 — DHEA well-being and body composition effects · Baulieu et al., 2000 — DHEAge trial: 1-year DHEA supplementation outcomes · Arlt et al., 1998 — 6-month DHEA replacement in adrenal insufficiency · Villareal & Holloszy, 2004 — DHEA effects on abdominal fat and insulin action

Pregnenolone — Reported Timeline

Sources: Marx et al., 2009 — Proof-of-concept trial with pregnenolone for cognition · Marx et al., 2014 — Randomized controlled trial of pregnenolone in schizophrenia · Brown et al., 2010 — Pregnenolone for cognition and mood in dual diagnosis patients

Who Reports the Most Benefit

Consistent with clinical trial data, users who report the most pronounced benefits tend to fall into specific categories:

• Individuals with documented low DHEA-S levels — supplementation produces a clear physiological change
• Postmenopausal women — where DHEA serves as a meaningful source of sex steroids
• Individuals with adrenal insufficiency or chronic adrenal stress
• Adults over 60 — where the age-related decline is most pronounced

Younger adults with normal DHEA-S levels tend to report fewer perceived benefits, consistent with the principle that supplementing a hormone that is already adequate produces limited clinical effect.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

DHEA Side Effects

Pregnenolone Side Effects

Theoretical Risks and Concerns

• Hormone-sensitive cancers: Because DHEA converts to sex hormones, individuals with a history of breast cancer, prostate cancer, ovarian cancer, or endometrial cancer should avoid DHEA supplementation unless explicitly cleared by their oncologist. The theoretical concern is that increased estrogen or testosterone could promote growth of hormone-receptor-positive tumors.
• Prostate health: DHEA's conversion to testosterone and DHT raises theoretical concerns about prostate stimulation. While clinical trials have not shown increased prostate problems, PSA monitoring is recommended for men.
• Hormonal cascading with pregnenolone: Because pregnenolone can convert to multiple downstream hormones, it is theoretically less predictable than DHEA supplementation — the body may preferentially convert it to cortisol, progesterone, or DHEA depending on enzymatic activity and physiological demand.
• Drug interactions: Both hormones may interact with hormone-sensitive medications, including oral contraceptives, hormone replacement therapy, aromatase inhibitors, and anti-androgen medications.

Contraindications

• Hormone-sensitive cancers (breast, prostate, ovarian, endometrial) — active or history
• Pregnancy and breastfeeding — no safety data
• Polycystic ovary syndrome (PCOS) — DHEA may worsen androgen excess
• Liver disease — steroid metabolism occurs primarily in the liver
• Children and adolescents — may interfere with normal hormonal development

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

United States

In the US, DHEA and pregnenolone occupy an unusual regulatory position. Despite being hormonal precursors with measurable effects on sex hormone levels, they are classified as dietary supplements — not drugs — under the Dietary Supplement Health and Education Act of 1994 (DSHEA). This means:

• They can be sold without a prescription in retail stores and online
• Manufacturers do not need to prove efficacy or safety before marketing
• The FDA does not review supplements for efficacy prior to sale
• Product quality, purity, and accurate labeling are the responsibility of the manufacturer
• Claims must be limited to "structure/function" claims (e.g., "supports healthy hormone levels") — not disease treatment claims

The exception is prasterone (Intrarosa), an intravaginal DHEA formulation that went through the full FDA drug approval process and is available by prescription only for vulvovaginal atrophy.

International Status

Athletic Testing

DHEA is listed on the World Anti-Doping Agency (WADA) prohibited list as an anabolic agent (S1.1b — Endogenous Anabolic Androgenic Steroids and their metabolites). Athletes subject to WADA or USADA testing cannot use DHEA supplements. Pregnenolone is not specifically listed but could theoretically alter steroid profiles detectable in doping tests.

Quality Concerns

Because dietary supplements are not subject to the same manufacturing and testing standards as pharmaceuticals, product quality varies:

• Independent testing (e.g., ConsumerLab, NSF International) has found some DHEA and pregnenolone products contain less active ingredient than labeled
• USP-verified or NSF-certified products provide greater quality assurance
• Pharmaceutical-grade products from reputable manufacturers are generally more reliable than budget alternatives

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Lab Monitoring Costs

Direct-to-consumer lab services (e.g., Quest Direct, Ulta Lab Tests) allow individuals to order these tests without a physician visit in many states, though interpretation by a healthcare provider is recommended.

Cost Comparison

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Question: Is DHEA a steroid?

Answer: Technically, yes — DHEA is a steroid hormone in the chemical sense (it has a steroid molecular structure). However, it is not an "anabolic steroid" in the way that term is commonly understood. DHEA is a weak prohormone that the body converts into more potent hormones. Its direct androgenic and anabolic effects are minimal compared to testosterone or synthetic anabolic steroids. That said, because it can increase testosterone and estrogen levels through peripheral conversion, it has hormonal effects that should be monitored (Labrie et al., 2005).

Question: Can DHEA cause cancer?

Answer: No clinical trial has demonstrated that DHEA supplementation causes cancer. However, because DHEA converts to sex hormones (testosterone, estradiol), there is a theoretical concern that it could promote the growth of hormone-receptor-positive cancers that already exist. Clinical trials lasting up to 2 years have not shown increased cancer incidence (Nair et al., 2006), but long-term safety data beyond 2 years is lacking. Individuals with a history of hormone-sensitive cancers should avoid DHEA unless cleared by their oncologist.

Question: Should I take DHEA if my levels are normal?

Answer: The rationale for DHEA supplementation is strongest when DHEA-S levels are below the age-appropriate reference range or below levels associated with optimal function. Supplementing DHEA when levels are already in the normal or high-normal range is less likely to produce benefit and may increase the risk of side effects from supraphysiologic hormone levels. Lab testing before initiating supplementation helps determine whether a physiological rationale exists (Baulieu et al., 2000).

Question: Will DHEA convert to estrogen in men?

Answer: Yes, it can. DHEA is converted to androstenedione and then to testosterone in peripheral tissues. Testosterone can then be converted to estradiol by the aromatase enzyme. In some men — particularly those with higher body fat (which contains more aromatase) — DHEA supplementation can raise estradiol levels. This is why estradiol monitoring is recommended for men taking DHEA. If estradiol rises excessively, dose reduction or discontinuation is appropriate (Labrie et al., 2005).

Myth: Pregnenolone is safer than DHEA because it is "further upstream."

Answer: This is a common claim in supplement marketing, but it is an oversimplification. The argument is that because pregnenolone sits at the top of the hormone cascade, the body can "choose" which downstream hormone to make from it, resulting in a more balanced effect. While the biochemistry is sound in principle, the body's enzymatic preferences are not always predictable. Supplemental pregnenolone may preferentially convert to one pathway over another depending on individual enzyme expression, stress levels, and other factors. Both hormones warrant monitoring, and neither should be assumed to be inherently "safe" simply based on its position in the biosynthetic pathway.

Question: Can I take DHEA and pregnenolone together?

Answer: Some practitioners recommend combining both hormones, using pregnenolone as a broad precursor and DHEA for more targeted androgenic/estrogenic support. This combination is used in clinical practice but has not been studied in controlled trials as a paired intervention. When combining, lower doses of each are typically used, and lab monitoring becomes more important to detect any excessive hormonal shifts.

Question: Why is DHEA banned in other countries?

Answer: Many countries classify DHEA as a hormonal substance or anabolic steroid precursor, which places it under pharmaceutical or controlled substance regulations. The US classification of DHEA as a dietary supplement under DSHEA (1994) is an exception rather than the international norm. Countries like Canada, the UK, and Australia require a prescription because they regulate hormonal substances more strictly than the US supplement framework does. The question of whether DHEA should be available OTC is a matter of regulatory philosophy rather than a reflection of its safety profile in either direction.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• DHEA is the most abundant circulating steroid hormone and functions as a prohormone that converts to testosterone and estrogen in peripheral tissues. Levels decline approximately 80% between peak (ages 20–30) and age 75.
• Pregnenolone is the "mother hormone" — the first steroid synthesized from cholesterol and the precursor to all other steroid hormones including cortisol, DHEA, progesterone, testosterone, and estrogen.
• Clinical trial results for DHEA supplementation are mixed. Early smaller trials (Morales 1994) showed improvements in well-being; larger trials (Baulieu 2000, Nair 2006) showed more modest or no significant benefits in healthy elderly adults. The strongest evidence supports DHEA replacement in women with adrenal insufficiency.
• Pregnenolone research is more limited and primarily focused on neuropsychiatric applications. Preliminary data suggests cognitive-enhancing properties, but large-scale trials in healthy adults are lacking.
• Both hormones are available OTC in the US under DSHEA, but are prescription-only or banned in many other countries.
• Side effects are primarily hormonal: acne, hair loss, elevated estrogen (DHEA); headache, drowsiness (pregnenolone). Both are generally well tolerated at standard doses.
• Lab monitoring is recommended for anyone supplementing with either hormone: DHEA-S, testosterone, estradiol, and PSA (men) at baseline and periodically.
• Cost is low at $10–$30/month for either supplement, making them among the most affordable hormone-related interventions available.

Questions to Ask a Provider

• What are my current DHEA-S levels, and are they below the optimal range for my age and sex?
• Given my health history, is DHEA or pregnenolone supplementation appropriate?
• What dose should I start with, and how often should labs be rechecked?
• Are there any interactions with my current medications?
• What specific labs should be monitored, and what are the target ranges?
• Should I take DHEA, pregnenolone, or both — and what is the rationale?
• Are there signs or symptoms that should prompt discontinuation?
• Would direct hormone replacement (testosterone, estrogen) be more appropriate than precursor supplementation?

Sources & Further Reading

Landmark Clinical Trials

• Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) — "Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age" — Journal of Clinical Endocrinology & Metabolism
• Baulieu EE, Thomas G, Legrain S, et al. (2000) — "Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study" — Proceedings of the National Academy of Sciences
• Nair KS, Rizza RA, O'Brien P, et al. (2006) — "DHEA in elderly women and DHEA or testosterone in elderly men" — New England Journal of Medicine

Pregnenolone Research

• Ritsner MS, Gibel A, Shleifer T, et al. (2010) — "Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia" — Journal of Clinical Psychiatry
• Marx CE, Bradford DW, Hamer RM, et al. (2011) — "Pregnenolone as a novel therapeutic candidate in schizophrenia" — Neuroscience
• Marx CE, Lee J, Suber F, et al. (2009) — "Proof-of-concept trial with pregnenolone targeting cognitive and negative symptoms in schizophrenia"

DHEA Metabolism and Intracrinology

• Labrie F, Luu-The V, Bélanger A, et al. (2005) — "Is dehydroepiandrosterone a hormone?" — Journal of Endocrinology
• Orentreich N, Brind JL, Rizer RL, Vogelman JH (1984) — "Age changes and sex differences in serum dehydroepiandrosterone sulfate" — Journal of Clinical Endocrinology & Metabolism

Additional Clinical Studies

• Arlt W, Callies F, van Vlijmen JC, et al. (1999) — "Dehydroepiandrosterone replacement in women with adrenal insufficiency" — New England Journal of Medicine
• Jankowski CM, Gozansky WS, Schwartz RS, et al. (2006) — "Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults" — Journal of Clinical Endocrinology & Metabolism
• Schmidt PJ, Daly RC, Bloch M, et al. (2005) — "Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression" — Archives of General Psychiatry
• Hazeldine J, Arlt W, Lord JM (2010) — "Dehydroepiandrosterone as a regulator of immune cell function" — Journal of Steroid Biochemistry and Molecular Biology

Regulatory References

• FDA: Dietary Supplement Overview and Regulation
• WADA: Prohibited List — S1 Anabolic Agents

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.